RecallRadar

FDA Drug recall D-0725-2021

Combipatch (estradiol/norethindrone acetate transdermal system) 0.05/0.25 mg per day 50/250 Twice Weekly Rx Only a) 2 Systems NDC 68968-052…

On 2021-08-25 the FDA classified a Class II recall of Combipatch (estradiol/norethindrone acetate transdermal system) 0.05/0.25 mg per day 50/250 Twice Weekly Rx Only a) 2 Systems NDC 68968-052… by Noven Pharmaceuticals, citing failed Stability Specifications; out of specification for shear.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0725-2021
ClassificationClass II
Statusongoing
Initiated2021-07-30
Published2021-08-25
Last updated2026-09-13 11:52 UTC
CompanyNoven Pharmaceuticals
DistributionUS

Product

Combipatch (estradiol/norethindrone acetate transdermal system) 0.05/0.25 mg per day 50/250 Twice Weekly Rx Only a) 2 Systems NDC 68968-0525-2; b) 8 Systems NDC 68968-0525-8, Mfd. by: Noven Pharmaceuticals, Inc., Miami, Florida 33186, Dist. by: Noven Therapeutics LLC, Miami, Florida 33186

Reason

Failed Stability Specifications; out of specification for shear.

Identifiers

ndc68968-0514-8
ndc68968-0525-8
ndc68968-0525-2
code_infoLots: 88540 Exp. 03/2022; 89118 Exp. 05/2022; 89244 Exp. 07/2022; 89244 (sample lot) Exp. 07/2022

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0725-2021%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.